FDA Inspection 1215040 — BioReliance Corporation
The FDA completed an inspection of BioReliance Corporation on August 4, 2023 in Rockville, MD. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- August 4, 2023
- Fiscal Year
- 2023
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Rockville, MD (United States)